Swiss National Bank Lexicon Pharmaceuticals, Inc. Transaction History

Swiss National Bank

$150 Billion
Q3 2024

A detailed history of Swiss National Bank transactions in Lexicon Pharmaceuticals, Inc. stock. As of the latest transaction made, Swiss National Bank holds 317,500 shares of LXRX stock, worth $225,425. This represents 0.0% of its overall portfolio holdings.

Number of Shares

317,500

Holding current value

$225,425

% of portfolio

0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 07, 2024	BUY	$1.51 - $2.39 $479,425 - $758,825	317,500 New	317,500 $498,000
Q3 2023 Nov 08, 2023	BUY	$1.06 - $2.33 $10,918 - $23,999	10,300 Added 4.44%	242,300 $264,000
Q2 2023 Aug 09, 2023	BUY	$2.15 - $3.49 $148,565 - $241,159	69,100 Added 42.42%	232,000 $531,000
Q1 2023 May 10, 2023	SELL	$1.99 - $2.68 $38,606 - $51,992	-19,400 Reduced 10.64%	162,900 $395,000
Q4 2022 Feb 08, 2023	BUY	$1.8 - $2.56 $17,100 - $24,320	9,500 Added 5.5%	182,300 $348,000
Q3 2022 Nov 09, 2022	BUY	$1.94 - $3.43 $62,080 - $109,760	32,000 Added 22.73%	172,800 $415,000
Q1 2022 May 09, 2022	BUY	$1.95 - $3.89 $26,325 - $52,515	13,500 Added 10.6%	140,800 $294,000
Q2 2021 Aug 06, 2021	BUY	$4.12 - $5.87 $524,476 - $747,251	127,300 New	127,300 $584,000
Q2 2020 Aug 05, 2020	SELL	$1.75 - $2.3 $162,249 - $213,242	-92,714 Closed	0 $0
Q1 2020 May 08, 2020	BUY	$1.8 - $4.28 $7,380 - $17,548	4,100 Added 4.63%	92,714 $181,000
Q2 2019 Aug 02, 2019	BUY	$5.35 - $7.11 $73,295 - $97,407	13,700 Added 18.29%	88,614 $557,000
Q4 2018 Feb 13, 2019	SELL	$6.15 - $10.51 $31,365 - $53,601	-5,100 Reduced 6.37%	74,914 $497,000
Q3 2017 Nov 03, 2017	BUY	$12.17 - $16.3 $973,770 - $1.3 Million	80,014	80,014 $983,000

Others Institutions Holding LXRX

# of Institutions

141

Shares Held

238M

Call Options Held

459K

Put Options Held

133K

View Full List

About LEXICON PHARMACEUTICALS, INC.

Ticker LXRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 188,726,000
Market Cap $134M
Description
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...

More about LXRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Swiss National Bank with notifications on news.

Account

Swiss National Bank Lexicon Pharmaceuticals, Inc. Transaction History